A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma

Cancer

Volumn 107, Issue 12, 2006, Pages 2826-2832

  Micallef, Ivana N M ^a   Kahl, Brad S ^b   Maurer, Matthew J ^a   Dogan, Ahmet ^a   Ansell, Stephen M ^a   Colgan, Joseph P ^a   Geyer, Susan ^a   Inwards, David J ^a   White, William L ^a   Habermann, Thomas M ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

DLBCL; Epratuzumab; ER CHOP; International Prognostic Index; non Hodgkin Lymphoma

Indexed keywords

ALLOPURINOL; ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; METHOTREXATE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 33845597766     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22342     Document Type: Article

References (37)

1. Elias L. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, Adriamycin, vincristine and prednisone (CHOP). Cancer. 1978;42:1705-1710.
2. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596-602.
3. Fisher RI. Diffuse aggressive lymphomas: increased survival after alternating flexible sequence of PROMACE and MOPP chemotherapy. Ann Intern Med. 1983;98:304-309.
4. Fisher RI, DeVita VTJ, Hubbard SM. Randomized trial of ProMACE-MOPP vs ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol. 1984;3:242.
5. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986;104:757-765.
6. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
7. Gordon LI, Harrington DP, Andersen I, et al. Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992;327:1342-1349.
8. Sertoli MR, Satini G. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trail by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1994;12:1366-1374.
9. Cooper IA, Wolff MM, Robertson TI. Randomized comparison of CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol. 1994;12:769-778.
10. Vose IM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-397.
11. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
12. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood. 1998;92:1927-1932.
13. Coiffier B, Lepage E, Briere I, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
14. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23:4117-4126.
15. Habermann TM, Weller EA, Morrison VA, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;102:6a. Abstract 8.
16. Habermann TM, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood. 2004;104:40a. Abstract 127.
17. Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-early stopping after the first interim analysis [abstract]. Proc Am Soc Clin Oncol. 2004; 23:556a. Abstract 6500.
18. Pfreundschuh MG, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
19. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23: 5027-5033.
20. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9: 3982S-3990S.
21. Cesano A, Gayko U, Brannan C, et al. Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted immunotherapy [abstract]. Blood. 2002;100:350a. Abstract 1358.
22. Stein R, Qu Z, Chen S, et al. Mechanisms of anti-lymphoma effects of the humanized anti-CD22 monoclonal antibody, epratuzumab and combination studies with anti-CD20 MAbs [abstract]. Blood. 2003;102:298b. Abstract 4917.
23. Gada P, Hernandez-Ilizaliturri FJ, Repasky EA, et al. Epratuzumab's predominant antitumor activity in vitro/in vivo against non-Hodgkin's lymphoma (NHL) is via antibody-dependent cellular cytotoxicity (ADCC) [abstract]. Blood. 2002;100:353a. Abstract 1367.
24. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3051-3059.
25. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti CD-22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res. 2004;10:5327-5334.
26. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:5044-5051.
27. Strauss SJ, Lister A, Morschauser F, et al. Multi-centre, Phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: promising preliminary results [abstract]. Proc Am Soc Clin Oncol. 2004;22:577s.
28. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter Phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24:3880-3886.
29. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
30. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive NHL: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329:987-994.
31. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
33. Pfreundschuh MG, Ho A, Wolf M, et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: rituximab as an "equalizer" in the MInT (MABTHERA International Trial Group) study. J Clin Oncol. 2005;23(suppl):567s. Abstract 6529.
34. Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood (ASH Annual Meeting Abstracts). 2005;106:9a. Abstract 13.
35. Morrison VA, Weller EA, Habermann TM, et al. Patterns of growth factor (GF) usage and febrile neutropenia (FN) among older patients (pts) with diffuse large B-cell lymphoma (DLBCL) treated with CHOP or R-CHOP: an intergroup experience (CALGB 9793, ECOG-SWOG 4494). Blood. 2004;104:904a. Abstract 3309.
36. McLaughlin P. Late-onset neutropenia following rituximab. Leuk Lymphoma. 2006;47:965-966.
37. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma. 2006;47:1013-1017.